MTX Contracts has been appointed to deliver the £33m transformation of the historic Royal Alexandra Hospital in Rhyl, North Wales.
The main design and build contract, awarded by Betsi Cadwaladr University Health Board, will see the contractor deliver a three-storey, 2,500m² facility using advanced elements of modern methods of construction.
MTX led the scheme through a two-stage procurement process under a pre-construction services agreement, working closely with NHS Wales Shared Services Partnership to develop a fully compliant design to RIBA Stage 4.
The contractor also worked closely with the health board during a series of carefully planned end-user sessions aimed at engaging the various departments that will operate within the new building.
Precisely engineered steel structural units will form the core fabric of the facility, with modules manufactured offsite while groundworks take place on site in order to streamline the overall construction programme.
Once the foundations and site preparations are complete, the prefabricated modules will be transported to site, craned into position and made watertight, enabling concrete floors to be poured and internal fit-out alongside the installation of mechanical and electrical services to progress quickly.
Work is expected to begin on site in the coming weeks, with completion scheduled for 2027.
The project represents the first phase of a £60m investment programme at the Royal Alexandra Hospital. A separate business case will be submitted by the health board for phase two, which will focus on redeveloping and improving the existing hospital estate.
MTX Contracts managing director David Hartley said: “Being chosen to partner with the health board in the creation of this important healthcare project reflects our strong track record in providing high-quality healthcare facilities across the UK.
“By employing hybrid methods of construction and our own unique skillset, we’re looking forward to delivering this vital new facility quickly, sustainably and cost-effectively, all whilst minimising disruption to existing patient pathways.”
